Moody National Bank Trust Division Sells 4,387 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

Moody National Bank Trust Division lessened its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGXGet Rating) by 54.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,741 shares of the medical research company’s stock after selling 4,387 shares during the period. Moody National Bank Trust Division’s holdings in Quest Diagnostics were worth $498,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. HM Payson & Co. lifted its stake in Quest Diagnostics by 0.7% in the 4th quarter. HM Payson & Co. now owns 13,838 shares of the medical research company’s stock valued at $2,394,000 after acquiring an additional 100 shares in the last quarter. Williams Jones Wealth Management LLC. lifted its stake in Quest Diagnostics by 2.0% in the 4th quarter. Williams Jones Wealth Management LLC. now owns 5,288 shares of the medical research company’s stock valued at $915,000 after acquiring an additional 102 shares in the last quarter. Personal CFO Solutions LLC lifted its stake in Quest Diagnostics by 1.6% in the 1st quarter. Personal CFO Solutions LLC now owns 6,382 shares of the medical research company’s stock valued at $873,000 after acquiring an additional 103 shares in the last quarter. ICW Investment Advisors LLC lifted its stake in Quest Diagnostics by 1.1% in the 1st quarter. ICW Investment Advisors LLC now owns 10,162 shares of the medical research company’s stock valued at $1,391,000 after acquiring an additional 111 shares in the last quarter. Finally, Freestone Capital Holdings LLC lifted its stake in Quest Diagnostics by 6.4% in the 4th quarter. Freestone Capital Holdings LLC now owns 2,025 shares of the medical research company’s stock valued at $350,000 after acquiring an additional 121 shares in the last quarter. Institutional investors own 88.87% of the company’s stock.

Quest Diagnostics Stock Up 0.4 %

DGX stock opened at $124.73 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.42 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $14.54 billion, a PE ratio of 10.38 and a beta of 1.01. Quest Diagnostics Incorporated has a 1-year low of $123.32 and a 1-year high of $174.16. The business’s 50 day simple moving average is $132.82 and its 200 day simple moving average is $135.69.

Quest Diagnostics (NYSE:DGXGet Rating) last posted its earnings results on Thursday, July 21st. The medical research company reported $2.36 earnings per share for the quarter, topping analysts’ consensus estimates of $2.26 by $0.10. The business had revenue of $2.45 billion for the quarter, compared to analyst estimates of $2.34 billion. Quest Diagnostics had a return on equity of 24.62% and a net margin of 14.02%. The firm’s revenue was down 3.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.18 EPS. As a group, research analysts anticipate that Quest Diagnostics Incorporated will post 9.68 EPS for the current year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 19th. Investors of record on Tuesday, October 4th will be issued a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 2.12%. The ex-dividend date is Monday, October 3rd. Quest Diagnostics’s payout ratio is presently 21.96%.

Insider Buying and Selling

In other Quest Diagnostics news, Director Timothy M. Ring sold 2,000 shares of the company’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $136.04, for a total value of $272,080.00. Following the transaction, the director now directly owns 23,933 shares of the company’s stock, valued at approximately $3,255,845.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.70% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. StockNews.com cut Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday. Morgan Stanley reiterated an “equal weight” rating and set a $142.00 price objective on shares of Quest Diagnostics in a research note on Monday, August 22nd. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $148.50.

Quest Diagnostics Profile

(Get Rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

See Also

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXGet Rating).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.